Enhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2004-03-01 / Eksp. Onkol. 2004 Mar;26(1):67-70MTH-68/H oncolytic viral treatment in human high-grade gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-03-01 / J. Neurooncol. 2004 Mar-Apr;67(1-2):83-93Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity
/in Dendritic Cells, Hyperthermia, International Publications /von 2004-03-01 / Cancer Sci. 2004 Mar;95(3):248-53Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2004-03-01 / J. Exp. Clin. Cancer Res. 2004 Mar;23(1):9-13Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution